Skip to main content
Top
Published in: Diabetologia 2/2018

01-02-2018 | Article

Aortic stiffness and ambulatory blood pressure as predictors of diabetic kidney disease: a competing risks analysis from the Rio de Janeiro Type 2 Diabetes Cohort Study

Authors: Claudia R. L. Cardoso, Nathalie C. Leite, Guilherme C. Salles, Marcel T. Ferreira, Gil F. Salles

Published in: Diabetologia | Issue 2/2018

Login to get access

Abstract

Aims/hypothesis

Diabetic kidney disease (DKD) is a microvascular complication associated with poor control of blood glucose and BP. We aimed to evaluate the predictors of development and progression of DKD in a cohort of high-risk individuals with type 2 diabetes, placing emphasis on ambulatory BP and arterial stiffness.

Methods

In a prospective study, 629 individuals without advanced renal failure had their renal function evaluated annually over a median follow-up period of 7.8 years. Ambulatory BP was monitored and aortic stiffness was assessed by carotid–femoral pulse wave velocity at baseline. Multivariate competing risks analysis with all-cause mortality, using the Fine and Gray approach, was used to examine the independent predictors of development and progression of DKD, a composite of development or progression of abnormal albuminuria and worsening of renal function (doubling of serum creatinine or progression to end-stage renal disease).

Results

At baseline, 197 individuals had DKD. During follow-up, DKD developed or progressed in 195 individuals, abnormal albuminuria developed or progressed in 125 individuals and renal function deteriorated in 91. After adjustments for baseline albuminuria and renal function, age, sex, diabetes duration and use of renin–angiotensin antagonists, poorer control of blood glucose (HR 1.17; 95% CI 0.98, 1.40; p = 0.09 for each 1 SD increment in mean first-year HbA1c), higher ambulatory systolic BP (HR 1.28; 95% CI 1.09, 1.50; p = 0.003, for each 1 SD increase in daytime systolic BP [SBP]) and increased aortic stiffness (HR 1.16; 95% CI 1.00, 1.34; p = 0.05) were independent predictors of development or progression of DKD. At baseline, ambulatory BP was a stronger predictor than BP measured in the clinic. Aortic stiffness predicted abnormal albuminuria development or progression (HR 1.26; 95% CI 1.02, 1.56; p = 0.036) whereas ambulatory BP was a stronger predictor of renal function deterioration (HR 1.32; 95% CI 1.09, 1.60; p = 0.005 for daytime SBP).

Conclusions/interpretation

Poor blood glucose and BP control and increased aortic stiffness were the main predictors of development or progression of DKD; ambulatory SBP was a better predictor than BP measured in the clinic. Ambulatory BP monitoring and assessment of aortic stiffness should be more widely used in clinical type 2 diabetes management.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zimmet PZ, Magliano DJ, Herman WH, Shaw JE (2014) Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2:56–64CrossRefPubMed Zimmet PZ, Magliano DJ, Herman WH, Shaw JE (2014) Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2:56–64CrossRefPubMed
2.
go back to reference Macisaac RJ, Ekinci EI, Jerums G (2014) Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 63(2 Suppl 2):S39–S62CrossRefPubMed Macisaac RJ, Ekinci EI, Jerums G (2014) Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 63(2 Suppl 2):S39–S62CrossRefPubMed
3.
go back to reference Jha V, Garcia-Garcia G, Iseki K et al (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382:260–272CrossRefPubMed Jha V, Garcia-Garcia G, Iseki K et al (2013) Chronic kidney disease: global dimension and perspectives. Lancet 382:260–272CrossRefPubMed
5.
go back to reference Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR (2012) Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172:761–769CrossRefPubMedPubMedCentral Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR (2012) Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172:761–769CrossRefPubMedPubMedCentral
6.
go back to reference Perkovic V, Heerspink HL, Chalmers J et al (2013) Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83:517–523CrossRefPubMed Perkovic V, Heerspink HL, Chalmers J et al (2013) Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83:517–523CrossRefPubMed
7.
go back to reference Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313:603–615CrossRefPubMed Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313:603–615CrossRefPubMed
8.
go back to reference Anderson RJ, Bahn GD, Emanuele NV, Marks JB, Duckworth WC, VADT Study Group (2014) Blood pressure and pulse pressure effects on renal outcomes in the veterans affairs diabetes trial (VADT). Diabetes Care 37:2782–2788CrossRefPubMedPubMedCentral Anderson RJ, Bahn GD, Emanuele NV, Marks JB, Duckworth WC, VADT Study Group (2014) Blood pressure and pulse pressure effects on renal outcomes in the veterans affairs diabetes trial (VADT). Diabetes Care 37:2782–2788CrossRefPubMedPubMedCentral
9.
go back to reference Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169CrossRefPubMedPubMedCentral Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169CrossRefPubMedPubMedCentral
10.
go back to reference Brunström M, Carlberg B (2016) Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 352:i717CrossRefPubMedPubMedCentral Brunström M, Carlberg B (2016) Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ 352:i717CrossRefPubMedPubMedCentral
11.
go back to reference Zoungas S, de Galan BE, Ninomiya T et al (2009) Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE. Diabetes Care 32:2068–2074CrossRefPubMedPubMedCentral Zoungas S, de Galan BE, Ninomiya T et al (2009) Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE. Diabetes Care 32:2068–2074CrossRefPubMedPubMedCentral
12.
go back to reference Ismail-Beigi F, Craven TE, O’Connor PJ et al (2012) Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 81:586–594CrossRefPubMed Ismail-Beigi F, Craven TE, O’Connor PJ et al (2012) Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 81:586–594CrossRefPubMed
13.
go back to reference Wong MG, Perkovic V, Chalmers J et al (2016) Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39:694–700CrossRefPubMed Wong MG, Perkovic V, Chalmers J et al (2016) Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39:694–700CrossRefPubMed
14.
go back to reference ABC-H Investigators, Roush GC, Fagard RH, Salles GF et al (2014) Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens 32:2332–2340CrossRef ABC-H Investigators, Roush GC, Fagard RH, Salles GF et al (2014) Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13,844 patients with hypertension. J Hypertens 32:2332–2340CrossRef
15.
go back to reference Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR (2013) Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens 31:2176–2186CrossRefPubMed Salles GF, Leite NC, Pereira BB, Nascimento EM, Cardoso CR (2013) Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. J Hypertens 31:2176–2186CrossRefPubMed
16.
go back to reference Palmas W, Moran A, Pickering T et al (2006) Ambulatory pulse pressure and progression of urinary albumin excretion in older patients with type 2 diabetes mellitus. Hypertension 48:301–308CrossRefPubMed Palmas W, Moran A, Pickering T et al (2006) Ambulatory pulse pressure and progression of urinary albumin excretion in older patients with type 2 diabetes mellitus. Hypertension 48:301–308CrossRefPubMed
17.
go back to reference Knudsen ST, Laugesen E, Hansen KW, Bek T, Mogensen CE, Poulsen PL (2009) Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients. Diabetologia 52:698–704CrossRefPubMed Knudsen ST, Laugesen E, Hansen KW, Bek T, Mogensen CE, Poulsen PL (2009) Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients. Diabetologia 52:698–704CrossRefPubMed
18.
go back to reference Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH (2011) Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 57:1511–1522CrossRefPubMed Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH (2011) Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 57:1511–1522CrossRefPubMed
19.
go back to reference Kimoto E, Shoji T, Shinohara K et al (2003) Preferential stiffening of central over peripheral arteries in type 2 diabetes. Diabetes 52:448–452CrossRefPubMed Kimoto E, Shoji T, Shinohara K et al (2003) Preferential stiffening of central over peripheral arteries in type 2 diabetes. Diabetes 52:448–452CrossRefPubMed
20.
go back to reference Liu JJ, Tavintharan S, Yeoh LY et al (2014) High normal albuminuria is independently associated with aortic stiffness in patients with type 2 diabetes. Diabet Med 31:1199–1204CrossRefPubMed Liu JJ, Tavintharan S, Yeoh LY et al (2014) High normal albuminuria is independently associated with aortic stiffness in patients with type 2 diabetes. Diabet Med 31:1199–1204CrossRefPubMed
21.
go back to reference Cardoso CR, Ferreira MT, Leite NC, Barros PN, Conte PH, Salles GF (2009) Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients. Atherosclerosis 205:472–476CrossRefPubMed Cardoso CR, Ferreira MT, Leite NC, Barros PN, Conte PH, Salles GF (2009) Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients. Atherosclerosis 205:472–476CrossRefPubMed
22.
go back to reference Sjöblom P, Nystrom FH, Länne T, Engvall J, Östgren CJ (2014) Microalbuminuria, but not reduced eGFR, is associated with cardiovascular subclinical organ damage in type 2 diabetes. Diabetes Metab 40:49–55CrossRefPubMed Sjöblom P, Nystrom FH, Länne T, Engvall J, Östgren CJ (2014) Microalbuminuria, but not reduced eGFR, is associated with cardiovascular subclinical organ damage in type 2 diabetes. Diabetes Metab 40:49–55CrossRefPubMed
23.
go back to reference Bouchi R, Babazono T, Mugishima M et al (2011) Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients. Diabetes Care 34:2570–2575CrossRefPubMedPubMedCentral Bouchi R, Babazono T, Mugishima M et al (2011) Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients. Diabetes Care 34:2570–2575CrossRefPubMedPubMedCentral
24.
go back to reference Sheen YJ, Lin JL, Li TC, Bau CT, Sheu WH (2013) Peripheral arterial stiffness is independently associated with a rapid decline in estimated glomerular filtration rate in patients with type 2 diabetes. Biomed Res Int 2013:309294CrossRefPubMedPubMedCentral Sheen YJ, Lin JL, Li TC, Bau CT, Sheu WH (2013) Peripheral arterial stiffness is independently associated with a rapid decline in estimated glomerular filtration rate in patients with type 2 diabetes. Biomed Res Int 2013:309294CrossRefPubMedPubMedCentral
25.
go back to reference Cardoso CR, Moran CB, Marinho FS, Ferreira MT, Salles GF (2015) Increased aortic stiffness predicts future development and progression of peripheral neuropathy in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia 58:2161–2168CrossRefPubMed Cardoso CR, Moran CB, Marinho FS, Ferreira MT, Salles GF (2015) Increased aortic stiffness predicts future development and progression of peripheral neuropathy in patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia 58:2161–2168CrossRefPubMed
26.
go back to reference Cardoso CR, Leite NC, Muxfeldt ES, Salles GF (2012) Thresholds of ambulatory blood pressure associated with chronic complications in type 2 diabetes. Am J Hypertens 25:82–88CrossRefPubMed Cardoso CR, Leite NC, Muxfeldt ES, Salles GF (2012) Thresholds of ambulatory blood pressure associated with chronic complications in type 2 diabetes. Am J Hypertens 25:82–88CrossRefPubMed
28.
go back to reference O’Brien E, Parati G, Stergiou G et al (2013) European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 31:1731–1768CrossRefPubMed O’Brien E, Parati G, Stergiou G et al (2013) European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 31:1731–1768CrossRefPubMed
29.
go back to reference Levey AS, Coresh J, Greene T et al (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766–772CrossRefPubMed Levey AS, Coresh J, Greene T et al (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766–772CrossRefPubMed
30.
go back to reference Van Bortel LM, Laurent S, Boutouyrie P et al (2012) Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 30:445–448CrossRefPubMed Van Bortel LM, Laurent S, Boutouyrie P et al (2012) Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 30:445–448CrossRefPubMed
31.
go back to reference Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef
32.
go back to reference Macisaac RJ, Jerums G (2011) Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 20:246–257CrossRefPubMed Macisaac RJ, Jerums G (2011) Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 20:246–257CrossRefPubMed
33.
go back to reference Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI (2017) Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig 8:6–18CrossRefPubMed Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI (2017) Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig 8:6–18CrossRefPubMed
34.
go back to reference Cardoso CR, Salles GF (2016) Aortic stiffness as a surrogate endpoint to micro- and macrovascular complications in patients with type 2 diabetes. Int J Mol Sci 17:2044CrossRefPubMedCentral Cardoso CR, Salles GF (2016) Aortic stiffness as a surrogate endpoint to micro- and macrovascular complications in patients with type 2 diabetes. Int J Mol Sci 17:2044CrossRefPubMedCentral
35.
go back to reference Moran A, Palmas W, Pickering TG et al (2006) Office and ambulatory blood pressure are independently associated with albuminuria in older subjects with type 2 diabetes. Hypertension 47:955–961CrossRefPubMed Moran A, Palmas W, Pickering TG et al (2006) Office and ambulatory blood pressure are independently associated with albuminuria in older subjects with type 2 diabetes. Hypertension 47:955–961CrossRefPubMed
36.
go back to reference Lurbe E, Redon J, Kesani A et al (2002) Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347:797–805CrossRefPubMed Lurbe E, Redon J, Kesani A et al (2002) Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347:797–805CrossRefPubMed
37.
38.
go back to reference Palmas W, Pickering T, Teresi J et al (2008) Nocturnal blood pressure elevation predicts progression of albuminuria in elderly people with type 2 diabetes. J Clin Hypertens (Greenwich) 10:12–20CrossRef Palmas W, Pickering T, Teresi J et al (2008) Nocturnal blood pressure elevation predicts progression of albuminuria in elderly people with type 2 diabetes. J Clin Hypertens (Greenwich) 10:12–20CrossRef
39.
go back to reference The ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRefPubMedCentral The ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRefPubMedCentral
40.
go back to reference Cooper-DeHoff RM, Gong Y, Handberg EM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61–68CrossRefPubMedPubMedCentral Cooper-DeHoff RM, Gong Y, Handberg EM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61–68CrossRefPubMedPubMedCentral
41.
go back to reference The DCCT/EDIC Research Group (2011) Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365:2366–2376CrossRefPubMedCentral The DCCT/EDIC Research Group (2011) Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365:2366–2376CrossRefPubMedCentral
42.
Metadata
Title
Aortic stiffness and ambulatory blood pressure as predictors of diabetic kidney disease: a competing risks analysis from the Rio de Janeiro Type 2 Diabetes Cohort Study
Authors
Claudia R. L. Cardoso
Nathalie C. Leite
Guilherme C. Salles
Marcel T. Ferreira
Gil F. Salles
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 2/2018
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4484-z

Other articles of this Issue 2/2018

Diabetologia 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.